CNS Pharmaceuticals, Inc. — Form 8-K

CNS Pharmaceuticals amended its 2020 Equity Plan effective September 30, 2026, increasing total authorized shares from 115,061 to 765,061 (adding 650,000 shares). The plan permits grants of stock options, restricted stock, stock units, and SARs to employees, directors, and consultants, with annual caps of $1.5M per employee for options/SARs and stock awards separately, and $300K per director. No repricing of options permitted without shareholder approval. Plan requires shareholder ratification at the September 30, 2026 annual meeting; if not approved within 12 months, the prior plan continues and this amendment has no effect.